AstraZeneca floats $6.9 billion in bonds

AstraZeneca announced it has issued $6.9 billion in bonds on the U.S. market, planning to use the proceeds to retire a chunk of the short-term debt it took on for the $15 billion MedImmune buyout. Its interest rates range from 6.45 percent on 30-year fixed-rate notes to 5.4 percent on 5-year fixed notes.

With a total of $13 billion in commercial paper, the company will still have several billions to convert to long-term debt. Today, the company named three banking advisors--Citigroup, Deutsche Bank, and HSBC--to explore an additional bond issue in Europe.

- read the release 
- see the report from CNBC

Related Articles:
AstraZeneca snares MedImmune in $15.6B buyout. Report
MedImmune CEO talks about AZ buyout. Report
AstraZeneca cuts 7,600 jobs. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.